Background
The overall cumulative live birth rate (CLBR) of poor ovary responders (POR) is extremely low. Minimal ovarian stimulation (MOS) suggested a relative realistic solution in ART for POR. Our study aimed to investigate whether multiple MOS strategy results in higher CLBR compared to GnRH antagonist protocol and the cost-effectiveness analysis in POR.
Methods
This retrospective study involved 699 patients (1058 cycles) who fulfilled the Bologna criteria in one center performed from 2010–2018. Specifically, 325 women (325 cycles) were treated with one time conventional GnRH antagonist ovarian stimulation (GnRH-antagonist). Another 374 patients (733 cycles) were treated with multiple minimal ovarian stimulations (MOS) including natural cycles. CLBR and cost-effectiveness analysis were performed comparing these two groups of women.
Results
GnRH- antagonist leads to more oocytes retrieved, more fertilized oocytes and more viable embryos compared to first MOS (p < 0.001) and the cumulative corresponding ones in multiple MOS (p < 0.001). For the first IVF cycle, GnRH- antagonist results in higher CLBR than MOS (12.92% versus 4.54%, Adjusted OR 2.606; 95%CI 1.386, 4.899, p = 0.003). However, GnRH-antagonist induces comparable CLBR with multiple MOS (12.92% versus 7.92%, Adjusted OR 1.702; 95%CI 0.971, 2.982, p = 0.063), but absolutely shorter time to live birth (9 (8, 10.75) months versus 11 (9, 14) months, p = 0.014) and similar financial expenditure compared to repeated MOS (20838 (17953, 23422) ¥ versus 21261.5 (15892.5, 35140.25) ¥, p = 0.13).
Conclusion
Both MOS and GnRH-antagonist provide low chance of live birth for poor responders. GnRH antagonist protocol is a sound choice for POR with comparable CLBR, shorter time to live birth and similar financial expenditure.